Breaking News, Financial News

Financial Report: Genentech 3Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genentech 3Q Revenues: $3.4 billion (+17%) 3Q Earnings: $731 million (+7%) YTD Revenues: $9.7 billion (+11%) YTD Earnings: $2.5 billion (+17%) Comments: U.S. product sales were $2.5 million in the quarter (+14%). Avastin sales were $704 million (+18%). Rituxan and Herceptin sales were both up 15% in the quarter to $655 million and $368 million, respectively. Lucentis sales were $225 million (+14%) and Xolair sales were $136 million (+12%). R&D expenses were $777 million in the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters